GMP-Ready Mammalian Cell Line Development
Product Description
Abzena
-
Country/Region:United Kingdom
-
Founded:2001
-
On CPHI since:2025
-
Certificates:3
-
Employees:250 - 499
Company types
Primary activities
Abzena
-
Country/Region:United Kingdom
-
Founded:2001
-
On CPHI since:2025
-
Certificates:3
-
Employees:250 - 499
Company types
Primary activities
More Products from Abzena (4)
-
Product De-Risk Your Complex Biologic with Developability & Manufacturability Assessments
Abzena’s integrated approach to developability assessment ensures that your biologic or bioconjugate is not only viable but optimized for success. By continually refining our selection criteria and asking the right questions early, we de-risk projects and move closer to developing ideal drugs. Our stage-a... -
Product Fully Integrated Development & Manufacturing Services for ADCs, AOCs, & RDCs
Move your bioconjugate to patients faster with one fully integrated partner across linker-payload design & synthesis, highly potent API (HPAPI) development & manufacturing, & advanced bioconjugation services. With over 25 years of experience, 3,000+ conjugates developed, and 1,400+ linker-payloads desig... -
Product Improved Design & Delivery of ADCs & AOCs with ThioBridge® Site-Specific Conjugation
Improve your ADC & AOC design and delivery with our ThioBridge® conjugation platform technology. Abzena's site-specific conjugation technology solution by provides a more uniform DAR & OAR profiles, stable linker attachment, and improved pharmacokinetic properties. ThioBridge® is important for the advance... -
Product Smarter Immunogenicity Testing with EpiScreen®2.0
Avoid issues later in the drug development process with smarter immunogenicity testing that improves candidate selection, reduces risk, and supports confident development decisions. Our enhanced bioassay platform EpiScreen® 2.0, is a comprehensive suite of assays that predict and evaluate potential risks ...



